Acute reactions to chemotherapy agents

Abstract

Acute reactions occur infrequently with chemotherapy agents. However, selected drugs have been known to be associated with severe hyper-sensitivity reactions, infusion reactions and other acute adverse events. The British Columbia Cancer Agency recently updated the list of selected drugs associated with hypersensitivity reactions and the minimum time that immediate physician coverage is needed.

Keywords

antineoplastic agents drug hypersensitivity immediate hypersensitivity

Get full access to this article

View all access options for this article.

References

B. C. Cancer Agency Provincial Systemic Therapy Program . Provincial Systemic Therapy Program Policy IV-10: Acute hypersensitivity reactions to chemotherapeutic agents. BC Cancer Agency , January 1998.

B. C. Cancer Agency Provincial Systemic Therapy Program . BCCA Protocol Summary for Management of Hypersensitivity Reactions to Chemotherapeutic Agents (SCDRUGRX). BC Cancer Agency , December 2005.

Timoney JP , Eagan MM , Sklarin NT. Establishing clinical guidelines for the management of acute hypersensitivity reactions secondary to the administration of chemotherapy/biologic therapy . J Nurs Care Qual 2003; 18: 80-86 .

Berlex . Campath® product monograph. Berlex , July 2005.

Graham ML. Pegaspargase: a review of clinical studies . Adv Drug Deliv Rev 2003; 55: 1293-1302 .

Bryant R. Use of a protocol to minimize hypersensitivity reactions with asparaginase administration . J Intraven Nurs 2001; 24: 169-173 .

Asselin BL. The three asparaginases. Comparative pharmacology and optimal use in childhood leukemia . Adv Exp Med Biol 1999; 457: 621-629 .

McEvoy GK ed. AHFS 2002 Drug Information. American Society of Health-System Pharmacists, Inc. , 2004.

Alcorn BT. Bleomycin hypersensitivity: a case report . Can J Hosp Pharm 1980; 33: 92-93 .

10.

ImClone Systems Incorporated, Bristol-Myers Squibb Company . Erbitux® product monograph. August 2005.

11.

Weidmann B , Mulleneisen N , Bojko P , et al. Hypersensitivity reactions to carboplatin. Report of two patients, review of the literature, and discussion of diagnostic procedures and management . Cancer 1994; 73: 2218-2222 .

12.

Markman M , Kennedy A , Webster K , et al. Clinical features of hypersensitivity reactions to carboplatin . J Clin Oncol 1999; 17: 1141-1145 .

13.

Tankanow RM. Docetaxel: a taxoid for the treatment of metastatic breast cancer . Am J Health Syst Pharm 1998; 55: 1777-1791 .

14.

Aventis Pharma Inc. Taxotere product monograph. 26 April 1999.

15.

Weiss RB. Hypersensitivity reactions . Semin Oncol 1992; 19: 458-477 .

16.

Hoetelmans RM , Schornagel JH , ten Bokkel Huinink WW , et al. Hypersensitivity reactions to etoposide . Ann Pharmacother 1996; 30: 367-371 .

17.

Sanofi-Synthelabo . Eloxatin: summary of product characteristics. 9 August 2002.

18.

Gowda A , Goel R , Berdzik J , et al. Hypersensitivity reactions to oxaliplatin: incidence and management . Oncology (Huntingt) 2004; 18: 1671-1675 ; discussion 6.

19.

Brandi G , Pantaleo MA , Galli C , et al. Hypersensitivity reactions related to oxaliplatin (OHP) . Br J Cancer 2003; 89: 477-481 .

20.

Bonosky K , Miller R. Hypersensitivity reactions to oxaliplatin: what nurses need to know . Clin J Oncol Nurs 2005; 9: 325-330 .

21.

Meyer L , Zuberbier T , Worm M , et al. Hypersensitivity reactions to oxaliplatin: cross-reactivity to carboplatin and the introduction of a desensitization schedule . J Clin Oncol 2002; 20: 1146-1147 .

22.

Lenz G , Hacker UT , Kern W , et al. Adverse reactions to oxaliplatin: a retrospective study of 25 patients treated in one institution . Anticancer Drugs 2003; 14: 731-733 .

23.

Thomas RR , Quinn MG , Schuler B , et al. Hypersensitivity and idiosyncratic reactions to oxaliplatin [see comment] . Cancer 2003; 97: 2301-2307 .

24.

Bhargava P , Gammon D , McCormick MJ. Hypersensitivity and idiosyncratic reactions to oxaliplatin [comment] . Cancer 2004; 100: 211-212 .

25.

Maindrault-Goebel F , Andre T , Tournigand C , et al. Allergic-type reactions to oxaliplatin: retrospective analysis of 42 patients . Eur J Cancer 2005; 41: 2262-2267 .

26.

Bernstein BJ. Docetaxel as an alternative to paclitaxel after acute hypersensitivity reactions . Ann Pharmac-other 2000; 34: 1332-1335 .

27.

Hoffmann-LaRoche . Rituxan product monograph. 21 June, 2000.

28.

McLaughlin P , Hagemeister FB , Grillo-Lopez AJ. Rituximab in indolent lymphoma: the single-agent pivotal trial . Semin Oncol 1999; 26: 79-87 .

29.

Onrust SV , Lamb HM , Balfour JA. Rituximab . Drugs 1999; 58: 79-88 ; discussion 9-90.

30.

Sehn LH , Donaldson J , Filewich A , et al. Rapid infusion rituximab in combination with steroid containing chemotherapy can be given safely and substantially reduces resource utilization . Blood 2004; 104-104 : abstract 1407.

31.

GlaxoSmithKline Inc. Bexxar™ product monograph. 18 August 2005.

32.

Cobleigh MA , Vogel CL , Tripathy D , et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-over-expressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease . J Clin Oncol 1999; 17: 2639-2648 .

33.

Hoffmann-LaRoche . Herceptin product monograph-important drug warning. 4 May, 2000.

34.

Hoffmann-LaRoche . Herceptin product monograph. 26 June, 2000.

35.

B. C. Cancer Agency Breast Tumour Group . BCCA protocol summary for adjuvant therapy for breast cancer using trastuzumab (Herceptin®) following the completion of chemotherapy (BRAJTR). BC Cancer Agency , 1 September 2005.

36.

B. C. Cancer Agency Breast Tumour Group . BCCA protocol summary for palliative therapy for metastatic breast cancer using trastuzumab (Herceptin®) (BRAVTR). BC Cancer Agency , 1 September 2005.